Literature DB >> 19679369

Effect of tight control of HbA1c and blood pressure on cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR).

Jan Cederholm1, Björn Zethelius, Peter M Nilsson, Katarina Eeg-Olofsson, Björn Eliasson, Soffia Gudbjörnsdottir.   

Abstract

AIM: To estimate hazard ratio (HR) of first incident fatal/non-fatal cardiovascular diseases (CVD) in female/male type 2 diabetic patients, with tight versus adverse control of HbA1c and blood pressure (BP) at baseline, age 30-70 years, no baseline CVD, followed for mean 5.7 years.
METHODS: 2593 patients with tight control of HbA1c <7.5% and BP < or = 140/90 mmHg (median 6.5%/130/80 mmHg), and 2160 patients with adverse control 7.5-9.0%/141-190/91-110 mmHg (median 8.1%/155/85 mmHg).
RESULTS: The hazard ratio (HR) for CVD with tight/adverse control was 0.67 (0.55-0.80; p<0.001), adjusting for age, sex, duration, hypoglycaemic treatment, smoking, BMI, lipid-lowering drugs, antihypertensive drugs, microalbuminuria. Adjusted HR for myocardial infarction, coronary heart disease, stroke and total mortality were 0.72 (0.56-0.92; p=0.01), 0.69 (0.55-0.86; p<0.001), 0.62 (0.45-0.84; p<0.001), 1.00 (0.72-1.39). The partial population-attributable risk percent for myocardial infarction, stroke and CVD was 23%, 33%, 29% if adverse HbA1c/BP control could be avoided, while 43%, 38%, 39% with overweight and smoking also avoided. Baseline lower BMI and absence of microalbuminuria were associated with tight control.
CONCLUSION: Median difference of HbA1c/BP 1.6%/25/5 mmHg between tight and adverse control considerably reduced the risk of cardiovascular diseases. The findings call for a multi-factorial approach to improve HbA1c, BP, obesity, smoking, and microalbuminuria.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19679369     DOI: 10.1016/j.diabres.2009.07.003

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  12 in total

1.  Additive effects of glycaemia and dyslipidaemia on risk of cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register.

Authors:  S Gudbjörnsdottir; B Eliasson; K Eeg-Olofsson; B Zethelius; J Cederholm
Journal:  Diabetologia       Date:  2011-06-15       Impact factor: 10.122

Review 2.  Target blood pressure in diabetes patients with hypertension--what is the accumulated evidence in 2011?

Authors:  Peter M Nilsson
Journal:  J Zhejiang Univ Sci B       Date:  2011-08       Impact factor: 3.066

3.  Risk factors for atrial fibrillation in type 2 diabetes: report from the Swedish National Diabetes Register (NDR).

Authors:  Björn Zethelius; Soffia Gudbjörnsdottir; Björn Eliasson; Katarina Eeg-Olofsson; Ann-Marie Svensson; Jan Cederholm
Journal:  Diabetologia       Date:  2015-06-19       Impact factor: 10.122

4.  Glycemic control and cardiovascular disease in 7,454 patients with type 1 diabetes: an observational study from the Swedish National Diabetes Register (NDR).

Authors:  Katarina Eeg-Olofsson; Jan Cederholm; Peter M Nilsson; Björn Zethelius; Ann-Marie Svensson; Soffia Gudbjörnsdóttir; Björn Eliasson
Journal:  Diabetes Care       Date:  2010-04-27       Impact factor: 19.112

5.  Diabetes, hypertension, and outcome studies: overview 2010.

Authors:  Peter M Nilsson; Jan Cederholm
Journal:  Diabetes Care       Date:  2011-05       Impact factor: 19.112

6.  A review of cardiovascular outcomes in the treatment of people with type 2 diabetes.

Authors:  George Dailey; Edward Wang
Journal:  Diabetes Ther       Date:  2014-12-17       Impact factor: 2.945

Review 7.  Pathophysiologic relationship between Alzheimer's disease, cerebrovascular disease, and cardiovascular risk: A review and synthesis.

Authors:  Cláudia Y Santos; Peter J Snyder; Wen-Chih Wu; Mia Zhang; Ana Echeverria; Jessica Alber
Journal:  Alzheimers Dement (Amst)       Date:  2017-02-09

8.  Independent contribution of A1C, systolic blood pressure, and LDL cholesterol control to risk of cardiovascular disease hospitalizations in type 2 diabetes: an observational cohort study.

Authors:  Gregory A Nichols; Sandra Joshua-Gotlib; Shreekant Parasuraman
Journal:  J Gen Intern Med       Date:  2013-01-24       Impact factor: 5.128

9.  Aspirin treatment and risk of first incident cardiovascular diseases in patients with type 2 diabetes: an observational study from the Swedish National Diabetes Register.

Authors:  Nils Ekström; Jan Cederholm; Björn Zethelius; Björn Eliasson; Eva Fhärm; Olov Rolandsson; Mervete Miftaraj; Ann-Marie Svensson; Soffia Gudbjörnsdottir
Journal:  BMJ Open       Date:  2013-04-20       Impact factor: 2.692

10.  Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial.

Authors:  Silvio E Inzucchi; Kamlesh Khunti; David H Fitchett; Christoph Wanner; Michaela Mattheus; Jyothis T George; Anne Pernille Ofstad; Bernard Zinman
Journal:  J Clin Endocrinol Metab       Date:  2020-09-01       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.